204 related articles for article (PubMed ID: 36185610)
21. D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms.
Liu M; Li C; Pazgier M; Li C; Mao Y; Lv Y; Gu B; Wei G; Yuan W; Zhan C; Lu WY; Lu W
Proc Natl Acad Sci U S A; 2010 Aug; 107(32):14321-6. PubMed ID: 20660730
[TBL] [Abstract][Full Text] [Related]
22. Resurrecting a p53 peptide activator - An enabling nanoengineering strategy for peptide therapeutics.
He W; Yan J; Li Y; Yan S; Wang S; Hou P; Lu W
J Control Release; 2020 Sep; 325():293-303. PubMed ID: 32653500
[TBL] [Abstract][Full Text] [Related]
23. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery.
Popowicz GM; Czarna A; Wolf S; Wang K; Wang W; Dömling A; Holak TA
Cell Cycle; 2010 Mar; 9(6):1104-11. PubMed ID: 20237429
[TBL] [Abstract][Full Text] [Related]
24. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.
Carvajal LA; Neriah DB; Senecal A; Benard L; Thiruthuvanathan V; Yatsenko T; Narayanagari SR; Wheat JC; Todorova TI; Mitchell K; Kenworthy C; Guerlavais V; Annis DA; Bartholdy B; Will B; Anampa JD; Mantzaris I; Aivado M; Singer RH; Coleman RA; Verma A; Steidl U
Sci Transl Med; 2018 Apr; 10(436):. PubMed ID: 29643228
[TBL] [Abstract][Full Text] [Related]
25. p53 regulation: teamwork between RING domains of Mdm2 and MdmX.
Wang X
Cell Cycle; 2011 Dec; 10(24):4225-9. PubMed ID: 22134240
[TBL] [Abstract][Full Text] [Related]
26. Designing dual inhibitors of Mdm2/MdmX: Unexpected coupling of water with gatekeeper Y100/99.
Lee XA; Verma C; Sim AYL
Proteins; 2017 Aug; 85(8):1493-1506. PubMed ID: 28425639
[TBL] [Abstract][Full Text] [Related]
27. AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex.
de Polo A; Luo Z; Gerarduzzi C; Chen X; Little JB; Yuan ZM
J Mol Cell Biol; 2017 Apr; 9(2):154-165. PubMed ID: 27927748
[TBL] [Abstract][Full Text] [Related]
28. Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development.
Guerlavais V; Sawyer TK; Carvajal L; Chang YS; Graves B; Ren JG; Sutton D; Olson KA; Packman K; Darlak K; Elkin C; Feyfant E; Kesavan K; Gangurde P; Vassilev LT; Nash HM; Vukovic V; Aivado M; Annis DA
J Med Chem; 2023 Jul; 66(14):9401-9417. PubMed ID: 37439511
[TBL] [Abstract][Full Text] [Related]
29. MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination.
Wang X; Wang J; Jiang X
J Biol Chem; 2011 Jul; 286(27):23725-34. PubMed ID: 21572037
[TBL] [Abstract][Full Text] [Related]
30. ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation.
Meulmeester E; Pereg Y; Shiloh Y; Jochemsen AG
Cell Cycle; 2005 Sep; 4(9):1166-70. PubMed ID: 16082221
[TBL] [Abstract][Full Text] [Related]
31. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.
Qin L; Yang F; Zhou C; Chen Y; Zhang H; Su Z
J Am Chem Soc; 2014 Dec; 136(52):18023-33. PubMed ID: 25453499
[TBL] [Abstract][Full Text] [Related]
32. d-Amino acid mutation of PMI as potent dual peptide inhibitors of p53-MDM2/MDMX interactions.
Li X; Liu C; Chen S; Hu H; Su J; Zou Y
Bioorg Med Chem Lett; 2017 Oct; 27(20):4678-4681. PubMed ID: 28916339
[TBL] [Abstract][Full Text] [Related]
33. Peptide activators of the p53 tumor suppressor.
Zhan C; Lu W
Curr Pharm Des; 2011; 17(6):603-9. PubMed ID: 21391910
[TBL] [Abstract][Full Text] [Related]
34. Mdm2 and MdmX RING Domains Play Distinct Roles in the Regulation of p53 Responses: A Comparative Study of Mdm2 and MdmX RING Domains in U2OS Cells.
Egorova O; Lau HH; McGraphery K; Sheng Y
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32075226
[TBL] [Abstract][Full Text] [Related]
35. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage.
Chen L; Gilkes DM; Pan Y; Lane WS; Chen J
EMBO J; 2005 Oct; 24(19):3411-22. PubMed ID: 16163388
[TBL] [Abstract][Full Text] [Related]
36. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
37. α-Helix-Mimicking Sulfono-γ-AApeptide Inhibitors for p53-MDM2/MDMX Protein-Protein Interactions.
Sang P; Shi Y; Lu J; Chen L; Yang L; Borcherds W; Abdulkadir S; Li Q; Daughdrill G; Chen J; Cai J
J Med Chem; 2020 Feb; 63(3):975-986. PubMed ID: 31971801
[TBL] [Abstract][Full Text] [Related]
38. Identification and characterization of the first small molecule inhibitor of MDMX.
Reed D; Shen Y; Shelat AA; Arnold LA; Ferreira AM; Zhu F; Mills N; Smithson DC; Regni CA; Bashford D; Cicero SA; Schulman BA; Jochemsen AG; Guy RK; Dyer MA
J Biol Chem; 2010 Apr; 285(14):10786-96. PubMed ID: 20080970
[TBL] [Abstract][Full Text] [Related]
39. Abnormal MDMX degradation in tumor cells due to ARF deficiency.
Li X; Gilkes D; Li B; Cheng Q; Pernazza D; Lawrence H; Lawrence N; Chen J
Oncogene; 2012 Aug; 31(32):3721-32. PubMed ID: 22120712
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluation of novel all-hydrocarbon cross-linked aza-stapled peptides.
Luo Z; Xu L; Tang X; Zhao X; He T; Lubell WD; Zhang J
Org Biomol Chem; 2022 Oct; 20(40):7963-7971. PubMed ID: 36190455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]